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A B S T R A C T
Cardiac resynchronization therapy (CRT), effected via biventricular pacing, has been 
shown to improve symptoms and left ventricular (LV) systolic function and to reduce 
mortality and hospitalizations among patients with moderate to severe heart failure 
symptoms (class III and IV), reduced LV ejection fraction (EF), and a wide QRS 
complex on electrocardiogram, usually in the form of left bundle branch block. Re-
cent evidence from randomized clinical trials and meta-analyses demonstrate that the 
beneficial effects of CRT on LV remodeling, heart failure symptoms, hospitalizations, 
and mortality also extend to patients with milder heart failure symptoms (class II). 
These data support the expansion of indications for CRT to less symptomatic patients 
with heart failure who have LVEF <0.35 and wide QRS duration in sinus rhythm. 
Accordingly the guidelines for CRT therapy by the European Society of Cardiology 
(ESC) and the American heart Association (AHA) have been updated to expand 
CRT indications to patients with milder heart failure symptoms.
Heart failure (HF) is a major international health problem with a substantial 
personal and economic impact. In the United States alone, there are approximately 6 
million HF patients, with >500,000 newly diagnosed patients each year. The estimated 
direct expenditure for healthcare cost approach $40 billion annually in the US. Recent 
advances in pharmacologic and nonpharmacologic therapies have improved outcomes 
in HF patients. Cardiac resynchronization therapy (CRT), effected via biventricular 
pacing, has been demonstrated to provide additional benefit in selected patients on 
guideline based optimal medical therapy with advanced heart failure symptoms.1-7 
Multiple clinical trials have demonstrated that CRT improves symptoms and left 
ventricular (LV) systolic function and reduces mortality and hospitalizations among 
patients with moderate to severe HF symptoms, reduced LV ejection fraction (EF), 
and a wide QRS complex on electrocardiogram.1–7 Cardiac resynchronization therapy 
also improves echocardiographic parameters, symptoms, hospitalizations, and mor-
tality in patients with NYHA Class III or IV symptoms with left ventricular systolic 
CARDIAC PACING & ICD UPDATE
Tufts University School of Medicine, 
Boston, MA, USA
HOSPITAL CHRONICLES 2012, VOLUME 7, SUPPLEMENT 1: 180–182
Correspondence to: 
N.A. Mark Estes III MD
Professor of Medicine
Tufts University School of Medicine
750 Washington Street
Boston, MA 02111
Tel: 617-636-6156
FAX: 617-636-4586
E-mail: nestes@tuftsmedicalcenter.
org
KEY WORDS: heart failure; 
cardiac dyssynchrony; cardiac 
resynchronization therapy; biventricular 
pacing; implantable cardioverter 
defibrillator; left bundle branch block; 
ischemic cardiomyopathy; non-
ischemic cardiomyopathy
AbbreviAtions
CRT = cardiac resynchronization therapy
EF = ejection fraction
HF = heart failure
ICD = implantable cardioverter 
defibrillator
LV = left ventric-le (-ular)
NYHA = New York Heart Association
Conflict of interest: none declared
CARDIAC RESYNCHRONIZATION THERAPY IN MILD HEART FAILURE
181
dysfunction, sinus rhythm, and a prolonged QRS duration.1-7 
These trials demonstrate a 22% relative risk reduction in all-
cause mortality and 37% relative risk reduction in heart failure 
hospitalization with CRT.1-7
Based on the improved outcomes in Class III and IV HF 
patients, clinical trials have been performed more recently to 
evaluate the role of CRT therapy in patients with less advances 
HF including patients with NYHA Class I and II symptoms.8-12 
Recent evidence from randomized clinical trials and meta-
analyses demonstrate that the beneficial effects of CRT on 
LV morphology, HF symptoms, hospitalizations, and mortality 
also extend to patients with mild HF.8-12
In the REVERSE trial, 600 patients with Class I or II 
heart failure, LVEF <40% and QRS >120 ms received a 
CRT-device.8 In a 2:1 fashion, they were randomized to CRT-
ON or CRT-OFF for 12 months. The primary endpoint was a 
composite heart failure response. This demonstrated a trend 
toward benefit with biventricular pacing.8 However, patients 
assigned to CRT-ON experienced a greater improvement 
in LV end-systolic volume index and other measures of LV 
remodeling. In addition, time-to-first HF hospitalization was 
significantly delayed in CRT-ON.8
In the larger MADIT-CRT trial, 1820 patients with Class 
I or II heart failure, LVEF <30%, and QRS duration <130 
ms were randomized to implantation with CRT-D or ICD 
only.9 Enrollment criteria included patients with class I and 
II symptoms with ischemic cardiomyopathy (ICMP) and class 
II symptoms with non-ischemic cardiomyopathy (NICMP). In 
follow-up of 2.4 years, the primary end point of heart failure 
hospitalization or death occurred in 187 of 1089 patients in the 
CRT-D group (17.2%) compared to 185 of 731 patients in the 
ICD-only group (25.3%).9 Mortality was low, thus the result 
was primarily driven by heart failure.9 In addition, LVEF was 
more likely to be improved in CRT patients (0.11 compared 
to 0.03). There was no difference in benefit between the ICMP 
and NICMP groups. Although no significant effect was seen in 
mortality, there were salutary effects seen on remodeling and 
heart failure events when CRT was utilized.9 In the MADIT-
CRT Trial, CRT-D was associated with a 34% reduction in 
the risk of death or heart failure events in asymptomatic or 
mildly symptomatic patients with ischemic or non-ischemic 
cardiomyopathy.9 This CRT-D benefit was driven by a 41% 
reduction in the risk of HF events.9 Subsequent analysis of 
the impact of CRT on echocardiographic parameters demon-
strates that CRT improves LV end-systolic volume, LV end-
diastolic volume and LVEF.9,12 Based on the MADIT-CRT 
Trial, CRT therapy is more effective in women than men, and 
in patients with wider than narrower QRS complexes.9 While 
this trial demonstrated that CRT-D is effective in preventing 
heart failure in mildly symptomatic at-risk cardiac patients with 
a 29% reduction in heart failure hospitalization, a mortality 
benefit was not found.9
More recently CRT was evaluated in mild to moderate 
heart failure in the RAFT trial.10 This trial enrolled patients 
with NYHA Class II and III heart failure patients who were 
receiving ICD implantation for primary or secondary pre-
vention of SCD. Inclusion criteria were patients with LVEF 
<30%, ICMP or NICMP, and intrinsic QRS duration >120 ms 
or paced QRS duration >200 ms.10 Patients were randomized 
to ICD only versus CRT-D in a 1:1 ratio.11 In the ICD group, 
patients were programmed to minimize pacing while the 
converse was true in the CRT-D group.10 Of note, because of 
published data during enrollment revealing decreased mortal-
ity with CRT alone in NYHA Class III heart failure, after 2006, 
the investigators of RAFT limited enrollment to Class II heart 
failure only. 10 Thus, of the total 1798 patients enrolled, the vast 
majority (1438 patients) had NYHA Class II heart failure. The 
primary outcome of death or hospitalization for heart failure 
occurred in 40.3% of patients in the ICD group compared to 
33.2% of patients in the CRT-D group (hazard ratio-HR 0.75, 
95% confidence intervals-CI 0.64-0.87).10 When only NYHA 
Class II heart failure patients were analyzed, there was also 
a decrease in the primary outcome (34.7% versus 27.3%, 
HR 0.73, 95% CI 0.61-0.88).10 Moreover, in Class II patients, 
unlike the MADIT-CRT and REVERSE trial, there was a 
significant decrease in death from any cause when CRT-D 
was placed rather than ICD alone (21.1% versus 15.5%, HR 
0.71, 95% CI 0.56-0.91).10
A recent meta-analysis was published including analysis of 
the REVERSE, MADIT-CRT, RAFT, and three smaller trials 
evaluating CRT in Class I and II heart failure.11 The analysis 
showed improvement in all-cause mortality (6 trials, 4572 
participants, pooled RR 0.83, 95% CI 0.72-0.96) and heart 
failure hospitalizations (4 trials, 4349 participants, pooled RR 
0.71, 95% CI 0.57-0.87) when CRT was utilized. There was no 
improvement in functional outcomes or quality of life which 
is not surprising as these patients had minimal symptoms at 
the time of implantation.11 Importantly, REVERSE, MADIT-
CRT, and RAFT drove the findings based on much larger 
population. Control patients in trials including NYHA class I 
or II symptoms had an ICD thus and optimal medical therapy, 
thus the benefits of CRT represent incremental benefits.
Important insights into the mechanisms of the beneficial 
effect of CRT have come from echocardiographic studies that 
have consistently demonstrated reverse remodeling in all HF 
functional classes.12 In patients with an increased QRS dura-
tion, especially left bundle-branch block, dysfunctional cardiac 
remodeling progresses over time.12 This results in an increased 
left ventricular volume and a decreased ejection fraction.12 The 
dyssynchronous cardiac contraction and increased myocardial 
strain is an essential pathophysiologic component of this re-
modeling.12 Cardiac resynchronization therapy provides more 
synchronous contraction with restoration of the left ventricular 
systolic contraction, including the torque motion that is an 
important part of normal cardiac contractility. This improve-
ment in contractile efficiency with CRT is associated with a 
182
HOSPITAL CHRONICLES 2010, VOLUME 7, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2012»
reduction in myocardial energy cost and oxygen consumption.12
Based on the available trials it is evident that CRT reduces 
all-cause mortality and heart failure hospitalization in patients 
with milder symptoms of heart failure (NYHA class I or II), left 
ventricular systolic dysfunction, and prolonged QRS duration. 
Randomized controlled trials provide sufficient evidence to 
support the expansion of indications for CRT to less symp-
tomatic patients with heart failure who have LVEF less than 
0.35 and wide QRS duration in sinus rhythm. Accordingly 
the guidelines for CRT therapy by the European Society of 
Cardiology (ESC) and the American heart Association (AHA) 
have been updated to expand the indications for CRT therapy 
to prevent HF progression in patients with both ischemic and 
non-ischemic cardiomyopathy, with impaired left ventricular 
function and bundle branch block.
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